AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Race Oncology Activates First Hong Kong Site for RC220 Phase 1 Trial in Advanced Solid Tumors
ByAinvest
Monday, Sep 1, 2025 8:18 pm ET1min read
Race Oncology has activated its first Hong Kong clinical site for the Phase 1 trial of RC220 in combination with doxorubicin in advanced solid tumors. Screening has commenced, with the first Hong Kong patient expected to begin treatment this month. Two patients have already been treated with RC220 in Australia, and recruitment is expected to accelerate as new sites open in Hong Kong and South Korea.
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) announced that the Hong Kong Department of Health has approved TIVDAK (tisotumab vedotin-tftv) for the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy [1]. This approval marks an important milestone for Zai Lab, strengthening its Women’s franchise in Greater China. TIVDAK is the first antibody-drug conjugate (ADC) therapy in cervical cancer, offering a clinically meaningful survival benefit to patients [1].The approval comes as Zai Lab continues to expand its commercial infrastructure for TIVDAK in Hong Kong, positioning it to reach patients without delay. TIVDAK is currently under regulatory review by China’s National Medical Products Administration (NMPA), which accepted the Biologics License Application in March 2025 [1].
Meanwhile, Race Oncology has activated its first Hong Kong clinical site for the Phase 1 trial of RC220 in combination with doxorubicin in advanced solid tumors. Screening has commenced, with the first Hong Kong patient expected to begin treatment this month [2]. Two patients have already been treated with RC220 in Australia, and recruitment is expected to accelerate as new sites open in Hong Kong and South Korea [2].
References:
[1] https://www.morningstar.com/news/business-wire/20250901343152/zai-lab-announces-approval-of-tivdak-for-patients-with-recurrent-or-metastatic-cervical-cancer-in-hong-kong
[2] https://www.morningstar.com/news/business-wire/20250901343152/zai-lab-announces-approval-of-tivdak-for-patients-with-recurrent-or-metastatic-cervical-cancer-in-hong-kong
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet